Black Diamond Therapeutics (NasdaqGS:BDTX) - Share price, News & Analysis

BDTX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

BDTX Stock Overview

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors.

Risk Analysis

Earnings are forecast to decline by an average of 7.5% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($82M)

Black Diamond Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Black Diamond Therapeutics
Historical stock prices
Current Share Price	US$2.27
52 Week High	US$12.96
52 Week Low	US$1.46
Beta	1.45
1 Month Change	51.33%
3 Month Change	-18.64%
1 Year Change	-82.35%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-94.25%

Shareholder Returns

	BDTX	US Biotechs	US Market
7D	12.9%	10.3%	6.6%
1Y	-82.3%	-24.4%	-18.5%

Return vs Industry: BDTX underperformed the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: BDTX underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is BDTX's price volatile compared to industry and market?
BDTX volatility
BDTX Average Weekly Movement	10.9%
Biotechs Industry Average Movement	13.0%
Market Average Movement	8.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: BDTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: BDTX's weekly volatility (11%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2014	86	David M. Epstein	https://www.blackdiamondtherapeutics.com

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations.

Black Diamond Therapeutics Fundamentals Summary

How do Black Diamond Therapeutics's earnings and revenue compare to its market cap?
BDTX fundamental statistics
Market Cap	US$82.38m
Earnings (TTM)	-US$120.80m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.7x

P/E Ratio

Is BDTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
BDTX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$120.80m
Earnings	-US$120.80m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-3.33
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did BDTX perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is BDTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BDTX?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for BDTX. This is calculated by dividing BDTX's market cap by their current preferred multiple.
What is BDTX's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$82.38m

BDTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does BDTX's PB Ratio compare to its peers?

BDTX PB Ratio vs Peers

The above table shows the PB ratio for BDTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PB	Estimated Growth	Market Cap
Peer Average	0.7x

Price-To-Book vs Peers: BDTX is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (0.7x).

Price to Earnings Ratio vs Industry

How does BDTX's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Book vs Industry: BDTX is good value based on its Price-To-Book Ratio (0.5x) compared to the US Biotechs industry average (1.6x)

Price to Book Ratio vs Fair Ratio

What is BDTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BDTX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	0.5x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BDTX's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of BDTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BDTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BDTX's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BDTX's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Black Diamond Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-7.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BDTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BDTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BDTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BDTX is forecast to have no revenue next year.

High Growth Revenue: BDTX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BDTX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Black Diamond Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-58.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BDTX is currently unprofitable.

Growing Profit Margin: BDTX is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: BDTX is unprofitable, and losses have increased over the past 5 years at a rate of 58% per year.

Accelerating Growth: Unable to compare BDTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BDTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: BDTX has a negative Return on Equity (-70.01%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Black Diamond Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BDTX's short term assets ($188.3M) exceed its short term liabilities ($19.5M).

Long Term Liabilities: BDTX's short term assets ($188.3M) exceed its long term liabilities ($27.5M).

Debt to Equity History and Analysis

Debt Level: BDTX is debt free.

Reducing Debt: BDTX has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BDTX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BDTX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 59.8% each year.

Discover healthy companies

Dividend

What is Black Diamond Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BDTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BDTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BDTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BDTX's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BDTX has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure

CEO

David M. Epstein (62 yo)

5.75yrs

Tenure

US$5,090,225

Compensation

Dr. David M. Epstein, Ph.D. is Co-Founder of Black Diamond Therapeutics, Inc. and serves as its President, Chief Executive Officer and Director at Black Diamond Therapeutics, Inc. since September 2016. He...

CEO Compensation Analysis

Compensation vs Market: David M.'s total compensation ($USD5.09M) is above average for companies of similar size in the US market ($USD758.64K).

Compensation vs Earnings: David M.'s compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: BDTX's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

Experienced Board: BDTX's board of directors are considered experienced (3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/06/24 00:00
End of Day Share Price	2022/06/24 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31